Experimental lung inflammation treatment trial shuts down after just one patient
NCT ID NCT04438382
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The approach remains unproven.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infliximab and intravenous immunoglobulin (IVIG)
What this could lead to
If it had succeeded, this could have pointed toward a better treatment for severe lung inflammation caused by immunotherapy in cancer patients.
What could go wrong
The trial was terminated early with only one participant, so no reliable conclusions can be drawn. The approach may not work or may have risks like infection or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bronson Battle Creek
Battle Creek, Michigan, 49017, United States
-
Cancer and Hematology Centers of Western Michigan - Norton Shores
Norton Shores, Michigan, 49444, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Lakeland Hospital Niles
Niles, Michigan, 49120, United States
-
Lakeland Medical Center Saint Joseph
Saint Joseph, Michigan, 49085, United States
-
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mercy Health Mercy Campus
Muskegon, Michigan, 49444, United States
-
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503, United States
-
Metro Health Hospital
Wyoming, Michigan, 49519, United States
-
Munson Medical Center
Traverse City, Michigan, 49684, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677, United States
-
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503, United States
-
VCU Massey Cancer Center at Stony Point
Richmond, Virginia, 23235, United States
-
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298, United States
-
West Michigan Cancer Center
Kalamazoo, Michigan, 49007, United States